Tag:
Depomed
Latest Headlines
Latest Headlines
UPDATED: Depomed shares crater on another Phase III miss for hot-flash drug
Depomed ( $DEPO ) disappointed in its third shot at a Phase III win for its drug Serada as a treatment for menopausal hot flashes, but the Menlo Park, CA-based firm's executives have given no
Depomed inks another deal for AcuForm, this time with Ironwood
Depomed has definitely learned the art of the deal. Ironwood Pharmaceuticals is the latest in a growing list of companies partnering with Depomed for its promising drug-delivery technology called
Depomed licenses Acuform to Boehringer
Depomed says Boehringer Ingelheim licensed worldwide rights to Depomed's Acuform gastric retentive drug delivery technology to develop and commercialize extended release metformin for type 2
Depomed gastric pill swells investor interest
Large fund investors appear to be hanging onto shares of Depomed when their more typical behavior following positive news from the FDA is to sell. The company's once-daily treatment for post-herpetic
Will Abbott end up marketing Depomed's Gralise?
What if you had a new drug, but no one to sell it? That's the predicament faced by Depomed, whose shingles-pain drug Gralise won FDA approval Friday. The company had a licensing deal with Solvay
Janssen pays upper GI bill to Depomed for AcuForm tech
Janssen Pharmaceutica, a unit of Johnson & Johnson, has bought nonexclusive rights to use Depomed's AcuForm drug delivery technology for use in combination therapy. AcuForm contains "unique
Janssen gets Acuform tech rights
Johnson & Johnson ( NYSE: JNJ ) unit Janssen Pharmaceutica has licensed worldwide rights to Depomed's ( NASDAQ: DEPO ) Acuform gastric retentive drug delivery technology. Depomed will receive a $5
Depomed recalls diabetes med on TBA contamination
Another drug recall underscores the pharma industry's recent manufacturing woes. Depomed has had to withdraw 52 lots of its diabetes drug Glumetza in the 500 mg dose after it found traces of a
Depomed readies another Phase III for Serada
Depomed is hoping that the third time proves to be the charm for Serada, its experimental drug for hot flashes. Last October the developer's stock price was pounded after it unveiled data from two
Depomed shares tank on disappointing hot-flash data
Investors quickly mugged Depomed shares ( DEPO ) this morning after hearing that two late-stage trials of Serada--intended to treat menopausal hot flashes--managed to successfully achieve only one of
